Arrowhead's ARO-MAPT tau data due H2 2026 in a field with no approved tau drug
The Phase 1/2a trial testing Arrowhead's RNAi tau-silencer in early Alzheimer's is designed for safety and PK first, with efficacy signals still to come.
Executive Summary
- Arrowhead Pharmaceuticals is preparing to disclose the first human data on its RNAi therapy designed to silence the tau gene in early Alzheimer's disease, testing whether a new subcutaneous delivery system can reach the brain safely.
- The trial's primary measure is adverse-event incidence, not cognitive or biomarker benefit, so the near-term disclosure will read as a tolerability and pharmacokinetic signal rather than an efficacy verdict.
- The program enters a tau-targeting field where several antibody and small-molecule candidates are already in Phase 2, but where RNAi delivery to the brain via subcutaneous dosing has not yet been tested in this disease.
- Enrollment and timelines have held steady since the study began recruiting, with no protocol instability signals to complicate the near-term data window.
The catalyst
Arrowhead said it expects initial data from the first parts of the AROMAPT-SC-1001 study, a Phase 1/2a trial of ARO-MAPT registered as NCT07221344, to be available in the second half of 2026. The trial is testing single and multiple doses of ARO-MAPT in healthy volunteers in parallel with multiple doses in patients with early Alzheimer's disease, defined as mild cognitive impairment due to Alzheimer's disease or mild Alzheimer's disease dementia. James Hamilton, the company's chief medical officer, said the trial is designed to test whether silencing tau gene expression "may prevent or reverse tau protein accumulation in subjects with early Alzheimer's disease, potentially preventing or slowing the progression of the disease". ArrowheadArrowhead Pharmaceuticals Initiates Phase 1/2a Study of ARO-MAPT for the Treatment of Alzheimer’s Disease and Other TauopathiesDec 8, 2025
Probability of SuccessBased on the AppliedXL Probability of Success model. For more information about the methodology, read the research here.
What the endpoint measures
The trial's registered primary endpoint is the number of participants with treatment-emergent adverse events over time, tracked across a placebo-controlled, dose-escalating design with a normal-saline comparator arm. Fifteen secondary endpoints cover pharmacokinetics and cerebrospinal fluid measures such as protein and glucose levels, but no cognitive or tau-biomarker efficacy measure is registered as primary. That structure means the H2-2026 disclosure is built to answer a tolerability and dosing question, not to establish clinical benefit. The trial enrolls adults aged 50 to 75 with a clinical diagnosis of early Alzheimer's disease supported by plasma, cerebrospinal fluid, or imaging biomarkers, with a target of 112 participants across sites in Canada and New Zealand. NCT07221344Study of ARO-MAPT-SC in Healthy Participants and Participants With Early Alzheimer's DiseaseNCT07221344
Trial operations
The trial moved from Not Yet Recruiting to Recruiting status in December 2025, and enrollment has held flat at its original 112-participant target since the study first posted, a routine hold rather than a change worth flagging. The registry shows no amendments to the primary completion date, which remains June 1, 2027, and no changes to the primary endpoint since the trial began recruiting. Arrowhead dosed its first subjects on December 8, 2025, and confirmed dosing again in a February 2026 update, consistent execution against its own guidance for the trial's early stages. NCT07221344+1Study of ARO-MAPT-SC in Healthy Participants and Participants With Early Alzheimer's DiseaseNCT07221344Arrowhead Pharmaceuticals Initiates Phase 1/2a Study of ARO-MAPT for the Treatment of Alzheimer’s Disease and Other TauopathiesDec 8, 2025
The competitive frame
Among industry-sponsored programs targeting MAPT specifically in early Alzheimer's disease, Merck's MK-2214 and a University of Southern California-sponsored AADvac1 study are the closest direct comparators by target and indication, both still in Phase 2. No other RNAi therapeutic has reached the clinic for Alzheimer's disease targeting MAPT; the nearest modality precedent is Alnylam's mivelsiran, an RNAi candidate against a different target (APP) in the same indication, and Regeneron's ALN-SNCA, an RNAi program in Parkinson's disease. Two prior Phase 1 trials studying MAPT in Alzheimer's disease completed without termination, though that base rate rests on a small sample and speaks to feasibility rather than to efficacy. No tau-directed therapy has yet won approval in Alzheimer's disease; the approved disease-modifying options in the indication are amyloid-targeting antibodies, a distinct mechanism this program does not compete against directly.
This analysis was produced using AI-assisted reporting systems, AppliedXL data, and official public records. These systems undergo editorial review, quality checks, and regular audits by human experts. Errors may still occur, as with any automated system. Always consult the linked primary sources. Read our AI Editorial Policy.